Engineering Novel Epitope-based Polyvalent Vaccine Against SARS-CoV-2
Channel: ISCB-SC Webinars
Date: 2021-02-23

"Infections and deaths due to COVID-19 pandemic is increasing dramatically day-by-
day, thereby scientists are rushing towards developing possible countermeasures to fight the deadly virus, SARS-CoV- 2. Therefore, in this study, immunoinformatics methods were exploited to design a novel epitope-based subunit vaccine against the virus. The highly antigenic, non-allergenic, non-toxic, non-human homolog, and 100% conserved epitopes were used for constructing the vaccine. In total, fourteen CTL epitopes and eighteen HTL epitopes were used to construct the vaccine. Thereafter, several in silico validations i.e., the molecular docking, molecular dynamics simulation (including the RMSF and RMSD studies), and immune simulation studies were also performed which predicted that the designed vaccine should be quite safe, effective, and stable within the biological environment. Finally, in silico cloning and codon adaptation studies were also conducted to design an effective mass production strategy of the vaccine. This study reveals the vaccine construct as a potential candidate which must undergo wet-lab based inspections."